Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.